Coya Therapeutics announced licensing of the exclusive, worldwide rights of a proprietary Exosome Engineering Technology, EET, from Carnegie Mellon University, CMU, with potential applications across multiple indications, including neurodegeneration, autoimmune, and oncology. Fred Grossman, President and CMO said “The science behind the technology is strong and has focused on overcoming the limitations of exosomes. We believe this technology can shape the future of targeted delivery of desired agents to address multiple conditions.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on COYA: